Alfredo Addeo MD

@Alfdoc2

Medical Oncologist, department of oncology at the University hospital of Geneva (HUG). All opinions expressed here are my own

Genève, Suisse

Born April 11

Replies Reposts Media

Alfredo Addeo MD
@Alfdoc2
Sep 17
thanks to highlight it
Hidehito HORINOUCHI
@HHorinouchi
Sep 16
🔥EGFR PACC mutations & exon 20 insertions in NSCLC: a rapidly evolving therapeutic landscape 🆙 @JCO_ASCO 🎯PACC (G719X, S768I, E709X, L747X): 2nd-gen TKIs preferred 🎯Common+PACC compound mutations: 3rd-gen TKIs 🎯Ex20ins: amivantamab, sunvozertinib (WU-KONG28), zipalertinib &
Alfredo Addeo MD
@Alfdoc2
Sep 16
Great timing for our new @JCO_ASCO review on PACC mutations & EGFR exon 20 insertions in NSCLC. “Uncommon EGFR” is no longer one disease , structure matters, and increasingly guides therapy. And #WCLC26 provided a perfect example: REZILIENT3 showed zipalertinib + chemo
ascopubs.org
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR–Mutant NSCLC: A Rapidly...
PURPOSEA structure-function classification has defined epidermal growth factor receptor (EGFR) P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) as distinct subsets of...
1
Alfredo Addeo MD
@Alfdoc2
Aug 10
Hot off the press Editorial in @JAMA_current « Is there still room for monotherapy in EGFR-mutated NSCLC? » With FLAURA2, MARIPOSA and now compelling data in EGFR/TP53 co-mutated disease, treatment intensification is increasingly becoming the standard. Key question remains: who
jamanetwork.com
Monotherapy in EGFR-Mutated Non–Small Cell Lung Cancer
In recent years, the therapeutic landscape of epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) has evolved rapidly, and combination strategies in the first-line...
2
Alfredo Addeo MD
@Alfdoc2
Jun 24
The randomized phase III trial evaluating time-of-day in NSCLC has been retracted due to major concerns regarding trial registration, protocol inconsistencies, and data integrity.nature.com/articles/s4159… This should not discourage researchers working on chronotherapy. The
nature.com
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3...
Nature Medicine - Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
1
Alfredo Addeo MD
@Alfdoc2
Jun 1
Negative phase III trial of concurrent thoracic RT in ES-SCLC receiving chemoimmunotherapy. TRT was initiated early (between cycles 2 and 3), and failed to improve outcomes: • Median OS 10.0 vs 11.8 months • No improvement in response rate • More adverse events and
2